Archives

Major Depressive Disorder (MDD) In Chronic Kidney Disease (CKD)
About This Event
Major Depressive Disorder (MDD) In Chronic Kidney Disease (CKD)
Major depressive disorder affects more than 260 million people worldwide.1 The reported prevalence of depression in patients with chronic kidney disease ranges from 20-65%.2 This presentation provides an overview of both MDD and CKD and discusses their overlap of symptomology.
1. World Health Organization. Fact Sheet on Depression. (2012) https://www.who.int/health-topics/depression#tab=tab_1
2. Teles F et al. Clinics (Sao Paulo). 2014 ;69(3):198-202.
Eight4Nine
Palm Springs, California 92262 + Google Map

Sucharita Somkuwar, PhD, BPharm
Otsuka Pharmaceutical Development & Commercialization, Inc.*
Areas of Expertise:
- Neurobiology of Psychiatric Disorders
- Pharmacology
- Substance Use Disorders
- Attention Deficit Hyperactivity Disorder

Marla Dallal, PharmD, RPH
Otsuka Pharmaceutical Development & Commercialization, Inc.*
Marla Dallal, PharmD, RPH is a Medical Science Liaison at Otsuka Pharmaceutical Development and Commercialization covering Southern California. She earned her Doctor of Pharmacy degree from the University of Southern California, School of Pharmacy in Los Angeles. While in pharmacy school, Dr Dallal pursued various clinical internships within the acute care and ambulatory care settings at Cedars-Sinai Medical Center and Kaiser Permanente. Prior to joining Otsuka, Dr Dallal held various positions within Medical Affairs at Amgen Inc covering the cardiometabolic and nephrology therapeutic areas. She also served as a preceptor at Amgen Inc, where she instructed pharmacy students on Advanced Pharmacy Practice rotations. She is currently licensed as a pharmacist in the state of California with the National Association Board of Pharmacy.
*Drs Somkuwar and Dallal are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC).